Neumora Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neumora Therapeutics, Inc. (NMRA) on June 15, 2026, covering events occurring between June 10 and June 15, 2026. The filing addresses a material amendment to the Company's loan agreement, the discontinuation of its lead drug candidate navacaprant, and a subsequent workforce reduction.
Key Financial Metrics and Liquidity
- Debt Restructuring: Entered into a Third Amendment to its Loan and Security Agreement on June 10, 2026, extending the interest-only period. If the second tranche of term loans is funded, interest-only payments continue through April 2029.
- Liquidity Covenant: A new minimum liquidity covenant becomes effective July 1, 2026. Requirements range from 50% to 110% of outstanding obligations or are waived entirely, depending on operational milestones and market capitalization.
- Restructuring Costs: Anticipated one-time restructuring costs of approximately $2 million to be incurred in the second quarter of 2026.
- Cost Savings: Expected annualized cost savings of approximately $10 million following a 35% reduction in force.
- Cash Runway: Management expects current cash and cash equivalents to provide a runway into the third quarter of 2027.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for the period.
Material Changes and Operational Updates
- Discontinuation of Navacaprant: On June 15, 2026, the Company announced the discontinuation of navacaprant for major depressive disorder (MDD) after Phase 3 KOASTAL-2 and -3 studies failed to achieve statistical significance on primary or key secondary endpoints.
- Study Results: In KOASTAL-2, navacaprant showed no significant difference from placebo (p = 0.813). In KOASTAL-3, results were also not statistically significant (p = 0.480).
- Workforce Reduction: Implemented a reduction in force of approximately 35% in connection with the discontinuation of navacaprant, expected to be completed in the second and third quarters of 2026.
Guidance, Outlook, and Risks
Following the restructuring, the Company is pivoting focus to its remaining pipeline candidates with the following anticipated milestones:
- NMRA-511 (Alzheimer's agitation): Complete multiple ascending dose cohort in Q4 2026; initiate Phase 2b dose-ranging study by end of 2026.
- NMRA-898 (Schizophrenia): Report Phase 1 data in the second half of 2026.
- NMRA-215 (Obesity): Complete repeat toxicology study mid-2026; initiate clinical studies by year-end 2026.
Risks and Contingencies: The filing highlights significant risks related to the uncertainty of clinical drug development, reliance on third-party CROs, potential side effects, and the sufficiency of capital resources to fund operations. The Company notes that actual results may differ materially from forward-looking statements.
Key Facts for Investor Verification
- Verify the specific terms of the Third Amendment to the Loan Agreement, particularly the conditions for the second tranche funding and the exact calculation of the minimum liquidity covenant.
- Confirm the exact timing and magnitude of the $2 million restructuring charge in the upcoming Q2 2026 earnings report.
- Monitor the progress of the remaining pipeline candidates (NMRA-511, NMRA-898, NMRA-215) against the stated 2026 milestones.
- Assess the impact of the 35% workforce reduction on the Company's ability to execute its revised clinical development plans.
- Review the detailed safety data for navacaprant to ensure no undisclosed liabilities exist despite the discontinuation.